KIMBERLY MEIXNER: Open Payments
NPI 1154545291 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$454 in 13 payments from 7 companies in 2025. Trend: 2023 $903 · 2024 $271 · 2025 $454
Food & beverage: $454
| Company | Payments | Amount |
|---|---|---|
| Adaptive Biotechnologies Corporation | 2 | $169 |
| Novartis Pharmaceuticals Corporation | 3 | $86 |
| Regeneron Healthcare Solutions, Inc. | 3 | $76 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $55 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Merck Sharp & Dohme LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
Products named: clonoSEQ, PLUVICTO, LIBTAYO, Nubeqa, Enhertu, Xofigo, KEYTRUDA, FRUZAQLA.
Industry payments across TX — which companies pay providers there.
